// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























4337 Abstracts

Personal neoantigen-targeting vaccination generates neoepitope-specific T cell responses in tumors of patients with glioblastoma

Derin B. Keskin - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Dexamethasone suppresses cytokine-induced dual oxidase 2 and VEGF-A expression in human pancreatic cancer cells in vitro and pancreatic cancer growth in xenografts

Yongzhong Wu - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Dexamethasone

An IgG1 version of the anti-TfR1 antibody ch128.1 shows significant antitumor activity against different xenograft models of multiple myeloma

Tracy R. Daniels-Wells - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Ceramide synthase-6 binding to CD95/Fas confers resistance to chemotherapy in T-cell acute lymphoblastic leukemia cells

Dattesh U. Verlekar - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

High response rates with entospletinib in patients with t(v;11q23.3);KMT2A rearranged acute myeloid leukemia and acute lymphoblastic leukemia

Alison R. Walker - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Glucocorticoid receptor (GR)-mediated activation of cyclic-adenosine monophosphate (cAMP) pathway gene expression following androgen receptor (AR) antagonism of prostate cancer

Tiha M. Long - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Prevention of stomatitis in patients with hormone receptorpositive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash.

Hope S. Rugo - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Dexamethasone

A clinical study of pretreatment with different doses of dexamethasone in the prevention of docetaxel-induced hypersensitivity.

Zhang ming Jun - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dexamethasone

A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

David Samuel DiCapua Siegel - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Hepatic artery infusion for recurrent or chemoresistant hepatic malignancy.

Harold J. Wanebo - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Intestinal carcinoid tumor

Dexamethasone

Impact of the rounding-off function of the computerized physician order entry system on the ordering time of chemotherapeutic regimens.

Kenji Tsuda - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dexamethasone

Impact of the rounding-off function of the computerized physician order entry system on dose variations of chemotherapeutic drugs.

Kenji Tsuda - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dexamethasone

Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL).

Elias Jabbour - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children with standard-risk acute lymphoblastic leukemia (SR ALL): Results of Childrens Oncology Group (COG) AALL0932.

Nina S. Kadan-Lottick - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Acute lymphoblastic leukemia

Dexamethasone

Final overall survival (OS) results from a phase II study of pemetrexed (Pem) and cisplatin (Cis) with concurrent thoracic radiation (RT) after Pem-Cis induction in patients with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC).

Silvia Novello - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Dexamethasone

Efficacy, safety, and cost efficiency of rituximab, gemcitabine, dexamethasone, and oxaliplatin (RGDOx) in B-cell NHL: Report of the prospective multicentric trial NCT01019863.

Marco Lefebvre - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-Cell Non-Hodgkin Lymphoma

Dexamethasone

Ikaros expression levels to predict response and survival following pomalidomide and dexamethasone in multiple myeloma (MM).

Yuan Xiao Zhu - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.

Jorge Monge - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN + DEX).

David Samuel DiCapua Siegel - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.

Paul G. Richardson - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Copyright © 2026. QuantiNova All rights reserved